<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335766">
  <stage>Registered</stage>
  <submitdate>30/07/2010</submitdate>
  <approvaldate>2/08/2010</approvaldate>
  <actrnumber>ACTRN12610000629033</actrnumber>
  <trial_identification>
    <studytitle>Effect of Combinatory Treatment with Lycopene/Soy Isoflavone on Glycemic Control and Plasma Lipid Profile in Individuals with Metabolic Syndrome</studytitle>
    <scientifictitle>Trial in Subjects with Mediterranean and Middle Eastern Ethnicity who have metabolic syndrome to evaluate the efficacy of a Lycopene/Soy Isoflavone nutritional supplement(LaFlavon) 7/50 mg pill taken daily for 3 months compared to placebo on glucose and insulin concentrations in this patient population.</scientifictitle>
    <utrn>U1111-1115-9761</utrn>
    <trialacronym>None</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metabolic Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>to study the effect of dietary supplementation with Lycopene (7mg) and Soy Isoflavones (50 mg), LaFlavon, taken by mouth once a day with food for ninety days on glucose and insulin plasma levels as well as plasma and tissue lipid concentrations in patients with metabolic syndrome.</interventions>
    <comparator>placebo (inactive ingredients), taken orally once a day for 90 days</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>a improvement in glucose and insulin levels in this patient population (metabolic syndrome) after 90 days of oral intake of LaFlavon (lycopene 7mg/soy isoflavones 50mg) measured by using a standard oral glucose tolerance test.</outcome>
      <timepoint>timeframe- baseline and 90 days after beginning treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>increased plasma concentration of the phytochemicals lycopene and soy isoflavones after 90 days oral intake of LaFlavon (lycopene 7 mg/ soy isoflavones 50 mg) measured by assessing serum concentration of these phytochemicals.</outcome>
      <timepoint>timeframe - baseline and 90 days after beginning treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>improvement in Endothelial Progenitor Cell (EPC) and Circulating Endothelial Cell (CEC) count after 90 days oral intake of LaFlavon measured using  plasma cell suspension ( buffy coat preparation) and analyzed by flow cytometry.</outcome>
      <timepoint>timeframe- baseline and 90 days after beginning treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>improvement in adipose tissue function in the regulation of lipid and glucose metabolism after 90 days oral intake of LaFlavon measured using both serum and subcutaneous fat bioptate sampling.</outcome>
      <timepoint>timeframe- baseline and 90 days after beginning treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>an improvement in the relationship between low-grade systemic inflammation(C-Reactive Protein, hsCRP) and chlamydial titres after 90 days oral intake of LaFlavon measured by both serum and fat bioptate sampling.</outcome>
      <timepoint>timeframe- baseline and 90 days after beginning treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Meditteranean and Middle Eastern(Arab) men and women between the ages of 18 and 75 (inclusive) who meet the International Diabetic Foundation(IDF) criteria for Metabolic Syndrome

Subjects must have a waist circumference adjusted for ethnicity (men &gt;37in (94cm), women &gt;31.5 in(80cm))


AND must meet two of the four following study criteria:

-  Elevated plasma triglyceride level at or &gt; 150mg/dl
-  Reduced plasma HDL level (HDL cholesterol at or &lt; 40  
   mg/dl in males, &lt;50 in females
-  Raised fasting plasma glucose level &gt;100mg/dl
-  Raised blood pressure(bp)  systolic bp&gt;130 mm/Hg
                                               diastolic bp &gt; 85  mm/Hg</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Any clinical evidence of type 2 diabetes or any pharmocological treatment for diabetes (any oral anti-hyperglycemic agent).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Tunisia</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>CamMedica, Ltd.</primarysponsorname>
    <primarysponsoraddress>Babraham Research Campus
Babraham, Cambridge
CB22 3AT, UK</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>CamMedica, Ltd.</fundingname>
      <fundingaddress>Babraham Research Campus
Babraham, Cambridge
CB22 3AT, UK</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This clinical trial is designed to explore the role of dietary supplementation with lycopene and soy isoflavones in the improvement of glucose metabolism in patients with metabolic syndrome.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hospital Sahloul De Sousse</ethicname>
      <ethicaddress>Republique Tunisienne
Ministere de la Sante Publique
Hospital Sahloul De Sousse
Route Ceinture-Cite Sahloul
4054 Sousse</ethicaddress>
      <ethicapprovaldate>5/03/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>4/03/2010</ethicsubmitdate>
      <ethiccountry>Tunisia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hospital Sahloul De Sousse</ethicname>
      <ethicaddress>Hospital Sahloul De Sousse
Republique Tunisienne
Ministere de la Sante Publique
Route Ceinture
Cite Sahloul 4054 Sousse</ethicaddress>
      <ethicapprovaldate>5/03/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Tunisia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Yuriy Bashmakov, M.D.</name>
      <address>Cambridge Theranostics, Ltd.
Babraham Research Campus
Babraham, Cambridge
CB22 3AT, UK</address>
      <phone>+44 797-159-8348</phone>
      <fax />
      <email>Yuriy@cammedica.com</email>
      <country>United Kingdom</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Regina Silver, RN, BA</name>
      <address>95 Rockland Street
Swampscott, Ma. 
USA 01907</address>
      <phone>00 +1 781-462-8539</phone>
      <fax />
      <email>rsilver@cambridgetheranostics.co.uk</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Regina Silver, RN, BA</name>
      <address>95 Rockland Street
Swampscott, Ma. 
USA 01907</address>
      <phone>00 +1 781-462-8539</phone>
      <fax />
      <email>rsilver@cambridgetheranostics.co.uk</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>